Benzinga’s Top Ratings Upgrades, Downgrades For June 6, 2023
Upgrades Evercore ISI Group upgraded the previous rating for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) from In-Line to Outperform. In…
Recap: Turning Point Brands Q1 Earnings
Turning Point Brands (NYSE:TPB) reported its Q1 earnings results on Wednesday, May 3, 2023 at 07:30 AM. Here’s…
Key Cannabis Exec Changes You Need To Know About: Lowell Farms & Other Marijuana Operators Strengthen Leadership Teams
Lowell Farms Strentghtens Board OF Directors
Lowell Farms Inc. (CSE: LOWL) (OTCQX: LOWLF), a California-based maker of Lowell Smokes, has named Summer Frein and Ann Lawrence to its board of directors.
Turning Point Brands Q3 Net Sales Stagnate YoY, What About Adjusted EBITDA?
Turning Point Brands, Inc. (NYSE: TPB), Q3 2022 net sales decreased 1.9% to $107.8 million compared to 109.9 million in Q3 2021.
Q3 2022 Financial Highlights
Earnings Outlook For Turning Point Brands
Turning Point Brands (NYSE:TPB) is set to give its latest quarterly earnings report on Wednesday, 2022-10-26. Here's what investors need to know before the announcement.
Analysts estimate that Turning Point Brands will report an earnings per share (EPS) of $0.61.
Key Cannabis Exec Changes You Need To Know About: Turning Point’s New CEO, Ayr Wellness’ New Pres & More
Turning Point Brand Names New CEO
Turning Point Brands, Inc. (NYSE: TPB) has tapped a long-tenured company executive Graham Purdy as CEO and board director following Yavor Efremov's resignation, less than a year following his appointment.
Turning Point Brands Appoints Graham Purdy As CEO; Cuts FY22 Guidance
Turning Point Brands Inc (NYSE:TPB) has appointed Graham Purdy as CEO and Board Director, effective as of October 16,…
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 528 companies set new 52-week lows.
This Analyst Boosts Price Target On Satsuma Pharmaceuticals By 200%? Plus UBS Predicts $38 For General Motors
SVB Leerink raised the price target on Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) from $5 to $15. SVB Leerink analyst Marc Goodman upgraded the stock from Market Perform to Outperform. Satsuma Pharmaceuticals shares fell 3.8% to close at $5.36 on Friday.
Tilray Brands To Rally Over 45%? Here Are 5 Other Price Target Changes For Monday
Cantor Fitzgerald raised Tilray Brands, Inc. (NASDAQ: TLRY) price target from $4.15 to $4.5. Cantor Fitzgerald analyst Pablo Zuanic maintained a Neutral rating on the stock. Tilray Brands shares fell 2.5% to $3.09 in pre-market trading.